Literature DB >> 10975611

CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10.

Y Nishida1, T Fukuda, I Yamamoto, J Azuma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10975611     DOI： 10.1097/00008571-200008000-00010

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  27 in total

1.  Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population.

Authors:  Akihiro Ishiguro; Takahiro Kubota; Hiroshi Sasaki; Yasuhiko Yamada; Tatsuji Iga
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

2.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

3.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

4.  Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.

Authors:  Qi Pei; Jinfu Peng; Hongyi Tan; Liu Yang; Xiding Yang; Li Liu; Shikun Liu; Hong Yuan; Guoping Yang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-27       Impact factor: 2.441

5.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

6.  Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers.

Authors:  Yali Shen; Zhu Luo; Qin Yu; Ying Wang; Jin Xiang; Jia Miao
Journal:  Eur J Clin Pharmacol       Date:  2017-02-28       Impact factor: 2.953

7.  Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.

Authors:  Hironari Tanaka; Takafumi Naito; Hikaru Sato; Takanori Hiraide; Yasuhide Yamada; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

8.  Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.

Authors:  Rui Chen; Haotian Wang; Jun Shi; Kai Shen; Pei Hu
Journal:  Eur J Clin Pharmacol       Date:  2015-05-13       Impact factor: 2.953

9.  The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.

Authors:  Xiujun Wu; Li Yuan; Jinliang Zuo; Jing Lv; Tao Guo
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

10.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.